Denali Therapeutics (DNLI)
(Delayed Data from NSDQ)
$15.43 USD
+0.47 (3.14%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $15.42 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Income Statements
Fiscal Year end for Denali Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 331 | 108 | 49 | 336 | 27 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 331 | 108 | 49 | 336 | 27 |
Selling & Adminstrative & Depr. & Amort Expenses | 527 | 449 | 344 | 273 | 240 |
Income After Depreciation & Amortization | -197 | -341 | -296 | 63 | -213 |
Non-Operating Income | 52 | 15 | 5 | 9 | 15 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -145 | -326 | -291 | 72 | -198 |
Income Taxes | 0 | 0 | -1 | 1 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -145 | -326 | -291 | 71 | -198 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -145 | -326 | -291 | 71 | -198 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -224 | -332 | -278 | 71 | -210 |
Depreciation & Amortization (Cash Flow) | -27 | 9 | 17 | 9 | 3 |
Income After Depreciation & Amortization | -197 | -341 | -296 | 63 | -213 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 137.37 | 125.53 | 121.53 | 112.70 | 95.61 |
Diluted EPS Before Non-Recurring Items | -1.06 | -2.60 | -2.39 | 0.63 | -2.07 |
Diluted Net EPS (GAAP) | -1.06 | -2.60 | -2.39 | 0.63 | -2.07 |
Fiscal Year end for Denali Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 1.27 | 294.12 | 35.14 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 1.27 | 294.12 | 35.14 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 132.57 | 115.07 | 123.64 | 155.96 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -132.57 | -113.80 | 170.48 | -120.82 |
Non-Operating Income | NA | 13.13 | 14.44 | 12.90 | 11.03 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -119.44 | -99.35 | 183.38 | -109.78 |
Income Taxes | NA | 0.03 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -119.47 | -99.35 | 183.38 | -109.78 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -119.47 | -99.35 | 183.38 | -109.78 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 138.25 | 137.65 | 140.93 | 136.53 |
Diluted EPS Before Non-Recurring Items | NA | -0.86 | -0.72 | 1.30 | -0.80 |
Diluted Net EPS (GAAP) | NA | -0.84 | -0.72 | 1.30 | -0.80 |